ArticleJournal of Cancer2024
Expression of programmed death receptor-1 ligand (PD-L1) in human cancer is of prognostic value and associated with macrophage infiltration.
Article in Journal of Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in PD-L1 Targeted Molecular Imaging Radiotracers Research: From Preclinical Exploration to Clinical Application.Molecular imaging and biology · 2026Review
- Clinical Significance of RBM15 in Gastric Cancer: A Multi-Database Validation.Current medicinal chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor immune microenvironment is a crucial factor influencing tumor progression, and its molecular mechanisms have become a key topic in immunotherapy research. Programmed death receptor-1 ligand (PD-L1, CD274) is a well-known immunosuppressive molecule that can mediate the immune escape of tumor cells. The aim of this study was to evaluate the significance of PD-L1 in human cancer by integrated bioinformatics analysis. Tumor IMmune Estimation Resource (TIMER), GEPIA, Kaplan-Meier plotter, TISIDB and Tumor Immune Single Cell Hub (TISCH) were used to perform the corresponding analysis. The results showed that PD-L1 was dysregulated in various cancers and was associated with the overall survival of cancer patients, which was associated with macrophage infiltration levels. Moreover, PD-L1 expression showed a significant correlation with macrophages and was universally expressed on tumor-associated macrophages (TAMs). Notably, the expression of PD-L1 on TAMs was found to be correlated with immunotherapy response in certain cancers based on analysis of single-cell RNA sequencing data. In conclusion, PD-L1 plays a significant role in cancer, which may partly be influenced by TAMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.